As scrutiny around skin substitute utilization increases, particularly in light of recent audit activity, providers should expect greater attention to documentation and the clinical justification ...

for Skin Substitute Grafts/Cellular and Tissue-Based Products. The new implementation date is January 1, 2026.

Celularity (CELU) welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date ...

A cyst can develop due to a clogged oil gland or hair follicle. Cysts feel like soft blisters when they are close to the skin’s surface, but they can feel like hard lumps when they develop ...

Berberine, or berberine hydrochloride, is a compound in several plants. It may help to treat diabetes, high cholesterol, high blood pressure, and more. However, more research is necessary ...

"The postponement provides a meaningful opportunity for Kerecis to share additional clinical data, including results from the largest skin substitute randomized controlled trial on diabetic foot ...

WASHINGTON – As part of the transition to the new administration, CMS is reviewing its coverage policies for skin substitute products. This means the final local coverage determinations for skin ...

2-Year U.S. Treasury Note Continuous Contract $103.816 0.004 0.00% 5-Year U.S. Treasury Note Continuous Contract $108.438-0.063-0.06% 10-Year U.S. Treasury Note Continuous Contract $111.156-0.266 ...